Wednesday, April 3, 2024 |
12:00 - 5:30 PM | Chicago Promenade |
Registration |
1:00 - 5:00 PM | Chicago Ballroom VII |
Platelet Disorder Support Association (PDSA) Pre-Summit Workshop |
Join PDSA for lunch and three fascinating presentations on Thrombocytopenia and Thrombosis: risk factors and underlying mechanisms with speakers Howard A. Liebman MA, MD, Professor of Medicine and Pathology, Keck School of Medicine, University of Southern California, and Ishac Nazy, Ph.D., Associate Professor at McMaster University, Hamilton, Ontario, Canada.
How Does ITP Happen? Old and New Mechanisms Thrombosis in ITP, An Often-Unexpected Complication in a Major Acquired Bleeding Disorder Thrombocytopenic and Thrombotic Syndromes Post-Vaccination for COVID-19 Lunch will be provided to workshop registrants. |
1:00 - 5:00 PM | Chicago Ballroom VI |
Hematology Workshop: Navigating Complex Cases in Bleeding Disorders |
TSHNA Hematology Workshop aims to tackle some of the more challenging and contemporary issues in bleeding disorders. This workshop is structured to provide an in-depth understanding of the topics through presentation of complex cases and dynamic panel discussions. Participants will emerge with enhanced clinical acumen, problem-solving skills, and the ability to apply theoretical knowledge in practical, real-world scenarios. This workshop is ideal for trainees and early-career physicians. The workshop is hosted by Association of Hemophilia Clinic Directors of Canada (AHCDC). |
1:00 - 5:00 PM | Chicago Ballroom IX-X |
Pre-Summit Workshop: Interesting Coagulation Cases |
Hosted by NASCOLA and ISLH Interesting and challenging cases in coagulation will be presented. Audience participation will be encouraged. |
1:00 |
Welcome & Intro From Islh And Nascola |
1:10 |
Case 1 McMaster University |
1:35 |
Case 2 University of Utah and ARUP Laboratories |
2:00 |
Case 3 Ohio State University |
2:25 |
Case 4 University of New Mexico and Tricore Laboratories |
2:50 |
Break |
3:10 |
Case 5 University of Minnesota |
3:35 |
Case 6 University of Utah and ARUP Laboratories |
4:00 |
Case 7 UT Southwestern |
4:25 |
Case 8 Stanford University |
4:50 |
Concluding Remarks |
Thursday, April 4, 2024 |
6:45 - 6:30 PM | Chicago Promenade |
Registration |
7:15 - 8:15 AM | Chicago Ballroom VI |
Ready, Set, Go! Shape the Future of Care in von Willebrand Disease (Sponsored by Octapharma) |
Join our distinguished faculty; Dr Veronica Flood, Dr Jill Johnsen, and Dr Shveta Gupta to explore the future of care in von Willebrand disease. The panel will discuss the diagnosis of von Willebrand disease, including identification of iron deficiency and genotyping, and the importance of prophylaxis in VWD patients. The results of the WIL-31 study will be presented, the largest prospective prophylaxis study in von Willebrand disease with an on-demand run-in study as an intra-individual patient comparator. We look forward to seeing you in Chicago! |
Chair(s): Veronica Flood |
7:15 |
Welcome And Introduction |
7:20 |
Identifying And Addressing Unmet Patient Needs In Vwd |
7:35 |
Insights From The Largest Prospective Prophylaxis Study In Vwd: Wil-31 |
7:50 |
Vwd Genotyping: Empowering Precise Diagnosis And Personalized Care |
8:05 |
Q&A And Concluding Remarks |
7:15 - 8:15 AM | Chicago Ballroom IX-X |
Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment, including the latest data in infants: Join the conversation with Dr. Mike Silvey (Sponsored by Genentech) |
Please join us for an engaging program led by Dr. Mike Silvey as he shares his perspectives on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal efficacy and safety data that is the foundation of the ongoing clinical trial program in patients with and without FVIII inhibitors, including an overview of real-world experience. He�ll also share updates from the latest trial in infants and previously untreated patients. The presentation will feature brain teasers, showcase social media that�s engaging the hemophilia community, and Mythbuster polls. Be sure to bring your questions to the Q&A following the program. |
8:30 - 9:45 AM | Sheraton Ballroom IV-V |
The Rise of the Patient Advocate - Impacting Research, Treatment, and Outcomes |
Chair(s): Lena Volland |
8:30 |
How The Clues And Pep Surveys Changed The Mental Health Landscape For Patients And Hcp'S |
8:55 |
The Role Of Social Media In Educating The Patients And Clinicians |
9:20 |
The Role Of Patient Advocacy Groups In Driving Innovation |
9:45 - 10:30 AM | Riverwalk AB |
Posters/Exhibits/Break |
Coffee break sponsored by Spark Therapeutics, Inc. |
P101 |
Unfractionated Heparin Use In The Setting Of Acute Pulmonary Embolism 1Medical College of Wisconsin, Milwaukee, WI, United States, 2Versiti Blood Center |
P102 |
In Vivo Volume Electron Microscopy Analysis At The Single Cell Level Reveals Regional Increases In Platelet Shape Dispersity Across A Mouse, Jugular Vein Puncture Wound Thrombus 1University of Arkansas for Medical Sciences, Little Rock, AR, United States, 2National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, United States |
P103 |
Long-Term Efficacy And Safety With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib In Patients With Immune Thrombocytopenia 1Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, 2University of Washington Medical Center, Seattle, WA, United States, 3Østfold Hospital Foundation, Gralum, Norway, 4Biostatistics, Sanofi, Bridgewater, NJ, United States, 5Sanofi, Cambridge, MA, United States, 6Department of Medicine, Hammersmith Hospital, London, United Kingdom |
P104 |
Risk Factors Associated With Venous Thromboembolism In Chronic Lymphocytic Leukemia 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States, 2Rutgers School of Public Health, Piscataway, NJ, United States, 3Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States |
P105 |
Outcomes And Predictors Of Immune Thrombocytopenia In Hospitalizations For Antiphospholipid Syndrome: A Nationwide Inpatient Sample Analysis 1Lincoln Medical and Mental Health Centre, Bronx, NY, United States, 2Montefiore Medical Centre, Bronx, NY, United States, 3University of Benin Teaching Hospital , Benin, Nigeria |
P106 |
The P.D1472H Polymorphism In The Vwf Gene Is Common In Indian Patients Postgraduate Institute of Medical Education and Research, Chandigarh, India |
P107 |
Iron Deficiency Has Generally Not Been Considered When Defining Sex-Based Hemoglobin Reference Intervals: A Systematic Review 1Department of Internal Medicine, University of British Columbia, Vancouver, BC, Canada, 2Hematology-Oncology Clinical Research Group, Division of Hematology-Oncology, St. Michael's Hospital, Toronto, Canada , Toronto, ON, Canada, 3Health Sciences Library, St. Michael’s Hospital, Li Ka Shing Knowledge Institute, Toronto, ON, Canada, 4Department of Medicine, University of Toronto, Toronto, ON, Canada, 5Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, United States, 6Department of Medicine, McMaster University, Hamilton, ON, Canada, 7Department of Laboratory Medicine & Pathobiology, Hematological Pathology, University of Toronto,, Toronto, ON, Canada, 8Departments of Medicine, and Laboratory Medicine and Pathobiology, St Michael’s Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada |
P108 |
Coagulation Profile And Clot Stiffness Analysis From Covid-19-Positive Patients Using A Novel Viscoelasticity Testing Technology 1Department of Mining and Materials Engineering, McGill University, Montreal, QC, Canada, 2Rheolution Inc., Montreal, QC, Canada, 3Department of Mathematics and Statistics, McGill University, Montreal, QC, Canada, 4Department of Medicine, Division of Hematology, McGill University Health Centre, McGill University, Montreal, QC, Canada, 5Department of Experimental Medicine, Division of Infectious Diseases, McGill University Health Centre, McGill University, Montreal, QC, Canada |
P109 |
Impact Of Anticoagulation In Acquired Hemophilia A University of Virginia, Charlottesville, VA, United States |
P110 |
Preliminary Findings Of Utilizing Aptt Assay As A Screening Tool For Lupus Anticoagulant Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States |
P111 |
Timeliness Of Hemostatic Therapy Administration For Patients With Bleeding Disorders In The Emergency Department Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada |
P112 |
Evaluation Of Real-World Treatment Patterns And Outcomes In Patients With Von Willebrand Disease Treated Prophylactically With Recombinant Von Willebrand Factor Across Treatment Centers In The United States 1Bleeding & Clotting Disorders Institute, Peoria, IL, United States, 2Tulane University School of Medicine, New Orleans, LA, United States, 3Analysis Group, Inc., Boston, MA, United States, 4Takeda Pharmaceuticals U.S.A., Inc, Lexington, MA, United States |
P113 |
The Relationship Between Different Pain Measures, Depression, And Social Support And Race And Ethnicity In Persons With Hemophilia. National Bleeding Disorders Foundation, New York, NY, United States |
P114 |
Bleeding Duet: A Case Of Simultaneous Acquired Factor Viii Deficiency And Acquired Von Willebrand Syndrome 1University of Western Ontario, Department of Hematology, London, ON, Canada, 2Queens University, Department of Hematology, Kingston, ON, Canada, 3University of Montreal, Department of Hematology, Montreal, QC, Canada |
P115 |
The Impact Of A High-Risk Anticoagulation Prescribing Stewardship Scoring Tool Implementation In An Inpatient Setting 1The Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD, United States, 2Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, United States |
P116 |
Does Unfractionated Heparin Versus Low Molecular Weight Heparin For Thromboprophylaxis Reduce Complications Near Delivery? Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, Washington, DC, United States |
P117 |
Rivaroxaban In Older Adults With Nonvalvular Atrial Fibrillation: Population-Based Analysis In Response To Updated Beers Criteria 1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States, 2Department of Medicine, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia , PA, United States |
P118 |
Monitoring Bivalirudin Therapy Using A Bivalirudin-Specific Chromogenic Anti-Iia Assay 1Department of Pathology, Division of Transfusion Medicine and Hemostasis, University of Texas Southwestern Medical Center, Dallas, TX, United States, 2Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States, 3UT Southwestern Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas, TX, United States |
P119 |
Influence Of Pharmaceutical Industry On Published Clinical Trial Results 1Global Thrombosis Forum , Suwanee, GA, United States, 2Loyola University , Chicago, IL, United States |
P120 |
Clinical Experience Using Regional Citrate Anticoagulation In Continuous Renal Replacement Therapy In A Neonate With Acute Kidney Failure: Case Report 1Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico, 2Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico, 3Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico, 4Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico |
10:30 - 11:30 AM | Sheraton Ballroom I-II |
Short Talks - Complications of Disease and Therapy in H&T |
Chair(s): Bethany Samuelson Bannow |
10:30 |
Efficacy Of Radiotherapy For Hemostasis In Tumor-Related Bleeding Oregon Health & Science University, Portland, OR, United States |
10:45 |
Osteoporosis And Fragility Fractures In Hemophilia And Von Willebrand Disease &Ndash; A Large National Claims Database Study 1University of Arkansas for Medical Sciences/ Arkansas Children's hospital, Little Rock, AR, United States, 2Centers for Disease Control and Prevention, Atlanta, GA, United States, 3Case Western Reserve University, Cleveland, OH, United States, 4Hemophilia & Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 5Centers for Bleeding and Clotting Disorders, Department of Pediatrics, Michigan State University, Lansing, MI, United States, 6Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, New Hyde Park, NY, United States, 7Division of Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI, United States, 8University of California San Francisco, San Francisco, CA, United States, 9Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa Health Care, Iowa City, IA, United States |
11:00 |
Healthcare Burden Of Venous Thromboembolism In Hospitalized Cancer Patients: Nationally Representative Estimates Using The Largest All-Payer Inpatient Database In The United States 1Southern Illinois School of Medicine P4P program, Springfield, IL, United States, 2Southern Illinois School of Medicine, Springfield, IL, United States, 3Vitalant Research Institute, San Francisco, CA, United States, 4University of Texas Southwestern School of Medicine, Dallas, TX, United States, 5Johns Hopkins University School of Medicine, Baltimore, MD, United States, 6Vitalant Corporate Medical Affairs, Scottsdale, AZ, United States |
11:15 |
Heparin-Induced Thrombocytopenia Among Cancer Hospitalizations: A Ten Year Retrospective Study 1John H. Stroger Jr Hospital , Chicago, IL, United States, 2Southern Illinois University Edwardsville, Edwardsville, IL, United States, 3University of Ilorin, Ilorin, Nigeria, 4Ladoke Akintola University of Technology, Ogbomosho, Nigeria, 5Tulane University School of Medicine, new orleans, LA, United States |
10:30 - 11:30 AM | Sheraton Ballroom IV-V |
Short Talks - Thrombosis - Innovations in AC |
Chair(s): Vinai Bhagirath |
10:45 |
Apixaban And Rivaroxaban Versus Warfarin As Atrial Fibrillation Or Venous Thromboembolism Treatment In Severely Obese Patients: A Multicenter Retrospective Analysis 1Department of Pharmacy, Ascension St. John Hospital, Detroit, MI, United States, 2Department of Pharmacy Practice, Wayne State University, Detroit, MI, United States, 3Department of Medical Education, Ascension St. John Hospital, Detroit, MI, United States |
11:00 |
Unraveling The Anticoagulant Functions Of Fv Using Monoclonal Antibodies 1Department of Pediatrics, The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, United States, 2The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States |
11:15 |
The Anticoagulated Trauma Patient In The Wilderness Oregon Health & Science University, Portland, OR, United States |
10:30 - 11:30 AM | Chicago Ballroom VII |
Short Talks - Industry Bleeding - No CME |
Chair(s): Julie Jaffray |
10:30 |
Improved Joint Health After Gene Therapy With Dirloctocogene Samoparvovec (Spk-8011) In People With Hemophilia A 1Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 2Department of Medicine, Division of Blood and Vascular Disorders, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, United States, 3Department of Pediatrics, Harvard Medical School, and the Division of Hematology and Oncology, Boston Children’s Hospital, Boston, MA, United States, 4Australian Centre for Blood Diseases, Monash University, Melbourne, Australia, 5Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States, 6St Michael's Hospital Haemophilia Treatment Centre, University of Toronto, Toronto, ON, Canada, 7Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, and the Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia, 8Mississippi Center for Advanced Medicine, Madison, MS, United States, 9Department of Medicine, UMKC School of Medicine, Kansas City, MO, United States, 10Department of Pediatrics, Oregon Health & Science University, Portland, OR, United States, 11Spark Therapeutics, Inc., Philadelphia, PA, United States |
10:45 |
Prophylactic Treatment Of Acquired Von Willebrand Disease In Non-Human Primates With Vga039, An Anti-Protein S Monoclonal Antibody Vega Therapeutics, Inc., South San Francisco, CA, United States |
11:00 |
Recombinant Adamts13 Prophylaxis In Patients With Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis From The Phase 3B Continuation Study 1APHP.6–Reference Center for Thrombotic Microangiopathies (CNR-MAT), Hôpital St Antoine, Paris, France, 2Takeda Development Center Americas, Inc., Cambridge, MA, United States, 3University College London Hospitals NHS Foundation Trust, London, United Kingdom, 4Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara, Japan, 5Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland, 6Duke University, Durham, NC, United States, 7Department of Internal Medicine, Ohio State University, Columbus, OH, United States, 8Department of Medicine 1, Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria, 9National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China, 10Department of Hematology and Medical Oncology, School of Medicine, Emory University, Atlanta, GA, United States, 11Department of Internal Medicine, Section of Hematology and Oncology, University of Oklahoma Health Science Center, Oklahoma City, OK, United States |
11:15 |
Initial Report Of Part B Phase 1/2 Efficacy And Safety Results For Bruton Tyrosine Kinase Inhibitor Rilzabrutinib In Patients With Relapsed Immune Thrombocytopenia 1Hammersmith Hospital, London, United Kingdom, 2Erasmus MC, University Medical Center, Rotterdam, Netherlands, 3Masaryk University Hospital, Brno, Czech Republic, 4The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, United States, 5Sanofi, Rotkreuz, LU, Switzerland, 6Sanofi, Cambridge, MA, United States, 7Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States |
11:45 - 12:45 PM | Chicago Ballroom VI |
Real-world experiences with ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc- Von Willebrand Factor XTEN Fusion Protein]: A first-in-class treatment option (Sponsored by Sanofi) |
Join us for a conversation about the mechanism of extension, pharmacokinetics, efficacy, dosing and safety information from the XTEND-1 clinical trial, as well as real-world clinical cases with ALTUVIIIO. This presentation will feature a live patient perspective. |
11:45 - 12:45 PM | Chicago Ballroom IX-X |
More Than Carriers: Recognizing and Managing Women and Girls With Hemophilia (Sponsored by Novo Nordisk) |
To highlight Novo Nordisk�s long-standing commitment to women and girls with rare bleeding disorders, this interactive program will discuss the unique challenges women and girls with hemophilia experience and will highlight the serious consequences that may arise in those who are not diagnosed and treated appropriately. Many women and girls are more than carriers, and they may experience added complications during menstruation, pregnancy, labor, and delivery. Practical guidance for managing hemophilia in women and girls will be presented, including available resources for providers and patients
|
12:45 - 1:30 PM | Riverwalk AB |
Posters/Exhibits/Break |
P201 |
Longitudinal Changes In Health-Related Quality Of Life (Hrql) During Anticoagulation Therapy In Cancer-Associated Venous Thromboembolism Treatment 1The University of Texas Health Science Center at Houston, Houston, TX, United States, 2The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico |
P202 |
Platelet Indices In Healthy Pregnancies State University of Ponta Grossa, Ponta Grossa, Brazil |
P203 |
Prevalence And Outcomes Of Heparin-Induced Thrombocytopenia In Inflammatory Bowel Disease: A Decade Study 1John H. Stroger Jr Hospital , Chicago, IL, United States, 2Southern Illinois University Edwardsville, Edwardsville, IL, United States, 3University of Ilorin, Ilorin, Nigeria, 4Ladoke Akintola University of Technology, Ogbomosho, Nigeria, 5Meharry Medical College, Nashville , TN, United States |
P204 |
Fixed-Dosing Of 4-Factor Prothrombin Complex Concentrate For Reversal Of Anticoagulation: Evaluating The Effectiveness, Safety, And Cost Savings 1Medical College of Wisconsin, Milwaukee, WI, United States, 2Froedtert Health, Milwaukee, WI, United States, 3Versiti Blood Research Institute, Milwaukee, WI, United States |
P205 |
Structured Education For Newly Diagnosed Persons With Von Willebrand Disease: A Hemophilia Treatment Center Quality Improvement Project Abstract Bleeding and Clotting Disorders Institute, Peoria, IL, United States |
P206 |
Safety And Efficacy Of The Anti-Tissue Factor Pathway Inhibitor Marstacimab In Participants With Severe Hemophilia Without Inhibitors: Results From The Phase 3 Basis Trial And Ongoing Long-Term Extension Study 1Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, Northwell Health, New Hyde Park, NY, United States, 2McMaster University, 237 Barton St. East, Hamilton, ON, Canada, 3Pfizer Inc, Collegeville, PA, United States, 4Pfizer Inc, New York, NY, United States, 5Pfizer Inc, Groton, CT, United States |
P207 |
Efficacy And Safety Of Eptacog Beta For Bleed Treatment In Adults And Adolescents With Hemophilia B And Inhibitors During Persept 1 1Central Michigan University College of Medicine/Children’s Hospital of Michigan, Carmen and Ann Adams Department of Pediatrics, Division of Hematology/Oncology, Detroit, NY, United States, 2Hemophilia and Thrombosis Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 3Cohen Children’s Medical Center, Northwell Health, New Hyde Park, NY, United States, 4Rainbow Babies & Children’s Hospital, Cleveland, OH, United States, 5Hemophilia Center of Central Pennsylvania, Hershey Medical Center, Hershey, PA, United States, 6UT Health San Antonio, San Antonio, TX, United States, 7Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, United States, 8Bleeding & Clotting Disorders Institute, Peoria, IL, United States, 9Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, United States, 10Center for Inherited Blood Disorders, Orange, CA, United States, 11Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, United States, 12Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, United States, 13LFB-USA, Inc., Framingham, MA, United States, 14HEMA Biologics, LLC, Louisville, KY, United States, 15GLOVAL LLC, Broomfield, CO, United States, 16Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, United States |
P208 |
Access To Factor Viii And Factor Ix To Persons With Hemophilia In Arkansas: A Quality Improvement Study 1University of Arkansas for Medical Sciences, Little Rock, AR, United States, 2Arkansas Children’s Hospital, Little Rock, AR, United States, 3American Thrombosis and Hemostasis Network , Rochester, NY, United States |
P209 |
Disease Burden, Quality Of Life, And Treatment Patterns In Patients With Hereditary Factor X Deficiency: Analysis Of Data From The Hereditary Factor X Deficiency In America Survey 1Kedrion Biopharma, INC., Fort Lee, NJ, United States, 2AESARA, INC., Chapel Hill, NC, United States, 3Versiti Blood Research Institute, Medical College of Wisconsin, and Children's Wisconsin, Milwaukee, WI, United States |
P210 |
Elevated Protein C Is Protective Against Post Thrombotic Syndrome 1University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 2University of Colorado Anschutz Medical Campus Research Laboratory, Aurora, CO, United States |
P211 |
Prophylactic Or Post-Traumatic Treatment Of Hypofibrinogenemia And Dysfibrinogenemia With Fibrgya In Eight Clinical Cases Bleeding and Clotting Disorder Institute, Peoria, IL, United States |
P212 |
Real-World Use Of Recombinant Factor Ix Fusion Protein In Previously Untreated Patients With Congenital Hemophilia B From The Athn 8 Study 1Rady Children’s Hospital San Diego, San Diego, CA, United States, 2American Thrombosis and Hemostasis Network, Rochester, NY, United States, 3Versiti Blood Research Institute, Waukesha, WI, United States, 4Yale University School of Medicine, New Haven, CT, United States, 5National Bleeding Disorders Foundation, New York, NY, United States, 6CSL Behring, King of Prussia, PA, United States, 7Children’s Mercy Hospital, Kansas City, MO, United States |
P213 |
The Effect Of Budd-Chiari Syndrome (Bcs) In Hospitalized Hepatocellular Carcinoma Patients (Hcc): A Nationwide Analysis. John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, United States |
P215 |
Anti-Factor Xi Antibodies Targeting The Apple 2 Domain And The Catalytic Domain Exert Distinct In Vitro Inhibitory Profiles On Coagulation Function Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States |
P216 |
ANtithroMbOsIS STEwardshIP As A Key Driver Within A Vte Center OF ExcelleNCe - Ambition Investigators University of New Mexico Hospital, Albuquerque, NM, United States |
P217 |
Anticoagulation Stewardship: Appropriate Use Of Apixaban And Rivaroxaban Factor Xa Levels In The Emergency Department Sanford USD Medical Center and Hospital, Sioux Falls, SD, United States |
P218 |
Cellular Indices Of Dvt 1Global Thrombosis Forum , Suwanee, GA, United States, 2Loyola University , Chicago, IL, United States, 3University of Westminster, London, United Kingdom |
P219 |
Are Medical Learners Adept At Recognizing Heavy Vaginal Bleeding? 1Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Department of Obstetrics and Gynecology, Toronto, ON, Canada, 3Division of Emergency Medicine, Toronto, ON, Canada, 4Division of Hematology/Oncology, St. Michael’s Hospital, Toronto, ON, Canada |
1:30 - 3:00 PM | Sheraton Ballroom I-II |
Identification and management of acquired bleeding in the acute care setting |
Chair(s): Bethany Samuelson Bannow |
1:30 |
Review Of Aquired Factor Deficiencies |
2:00 |
Laboratory Tools To Identify Acquired Coagulation Factor Abnormalities |
2:30 |
Management Considerations In The Surgical Setting Of Suspected Aquired Factor Deficiencies |
1:30 - 3:00 PM | Sheraton Ballroom IV-V |
Unbiased tech approaches for hematological discoveries |
Chair(s): Jordan Shavit |
1:30 |
Deep Mutational Scanning To Probe Function Of Coagulation Proteins |
2:00 |
Genetic Engineering Of Megakaryocytes To Uncover Functions Of Platelet Proteins |
2:30 |
Mass Spectrometry Glycomics And Determination Of Gpib Glycosites |
1:30 - 3:00 PM | Chicago Ballroom VII |
Taking the result to the patient - laboratory considerations in thrombosis |
Chair(s): William Dager |
1:30 |
Laboratory Considerations On Doac Levels (Including Precision And What We'Ve Learned From External Qa&Semi; Comment On Andexanet) |
2:00 |
Doac - When To Measure Levels And How To Interpret: On-Treatment Vs Therapeutic Range |
2:30 |
Advances In Testing For Aps - Beyond Sapporo (Titres, Isotypes, Non-Criteria Antibodies) |
3:00 - 3:45 PM | Riverwalk AB |
Posters/Exhibits/Break |
P301 |
Novel Point-Of-Care (Poc) Platform For Direct Oral Anticoagulants (Doac) And Vitamin K Antagonists (Avk) Testing: Microdoac And Microinr Assays R&D Department, iLine Microsystems S.L., San Sebastián/Donostia, Spain |
P302 |
Red Blood Cell Haemolysis And Platelet Activation : The Forgotten Players Of Hypercoagulability University of Westminster, London, United Kingdom |
P303 |
Hmb-001 For Prophylactic Treatment Of Glanzmann Thrombasthenia: Phase 1/2 Trial Insights 1Queen Mary University of London, London, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom, 3Comprehensive Care Haemophilia Centre, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 4Hemab Therapeutics, Cambridge, MA, United States, 5Richmond Pharmacology, London, United Kingdom |
P304 |
Investigating The Relationship Between D Dimer Levels And Viscoelastic Characteristics Of Blood Clots Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States |
P305 |
Transfusion Trends In The Obstetric Population With Analysis Of A Soft Stop Transfusion Emr Alert 1Department of Obstetrics and Gynecology, George Washington University , Washington, DC, United States, 2Department of Pathology, George Washington University, Washington, DC, United States |
P306 |
The Burden Of Hemophilia In The Us: Methods And Results From The Cost Of Hemophilia: A Socioeconomic Survey (Chess) Us (2022) 1Hematology Utilization Group Study (HUGS), Walnut Creek, CA, United States, 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Italy, 3Humanitas University, Pieve Emanuele, Milan, Italy, 4HCD Economics, Knutsford, United Kingdom, 5World Federation of Hemophilia, Montreal, QC, Canada, 6Irish Haemophilia Society Ltd, Dublin, Ireland, 7Trinity College, Dublin, Ireland, 8The Haemophilia Society, London, United Kingdom, 9Federación Española de Hemofilia (FedHemo), Madrid, Spain, 10Italian Federation of Haemophilia Associations (FedEmo), Rome, Italy, 11Association Française des Hémophiles (AFH), Paris, France, 12Faculty of Health and Social Care, University of Chester, Chester, United Kingdom |
P307 |
Hemostatic Outcome Of Surgical Procedures In Patients With Hemophilia Receiving Concizumab Prophylaxis: Data From The Phase 3 Explorer7 And Explorer8 Trials 1Penn State Health Milton S. Hershey Medical Center, Hershey, PA, United States, 2McMaster Children’s Hospital, McMaster Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada, 3Royal Children’s Hospital Melbourne, Victoria, Australia, 4Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 5Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy, 6Hospital Regional Universitario de Málaga, Málaga, Spain, 7The Haemophilia Centre, Department of Haematology, Aarhus University Hospital, Aarhus, Denmark, 8Novo Nordisk A/S, Søborg, Denmark, 9Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan, 10Novo Nordisk Inc., Plainsboro, NJ, United States |
P308 |
Athn Transcends &Ndash; Hemophilia Gene Therapy Outcomes Arm: A Long-Term Follow-Up Study On Safety And Effectiveness Of Gene Therapy In People With Hemophilia 1Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Children’s Hospital, Iowa City, IA, United States, 2CSL Behring, King of Prussia, PA, United States, 3National Bleeding Disorders Foundation, New York, NY, United States, 4Yale University School of Medicine, New Haven, CT, United States, 5American Thrombosis and Hemostasis Network, Rochester, NY, United States, 6Hemophilia Treatment Center St. Jude’s Children’s Research Hospital, Memphis, TN, United States |
P309 |
A Phase 3, Randomized, Active-Control Study Of Four-Factor Prothrombin Complex Concentrate Versus Frozen Plasma In Bleeding Adult Cardiac Surgery Patients 1University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Queen’s University, Kingston, ON, Canada, 4Kingston Health Sciences Centre, Kingston, ON, Canada, 5University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States, 6Octapharma AG, Lachen, Switzerland, 7Octapharma USA, Paramus, NJ, United States, 8Duke University School of Medicine, Durham, NC, United States |
P310 |
Vitamin D Deficiency In Persons With Bleeding Disorders &Ndash; A Single Center Experience Rush Hemophilia and Thrombophilia Center, Chicago, IL, United States |
P311 |
Genomic Variations In Factor Vii Deficiency Predisposing To Thrombophilia: A Case Of Sinus Venous Thrombosis In A Patient With Factor Vii Deficiency 1Bridgeport Hospital/Yale New Haven Health , Bridgeport, CT, United States, 2Yale Smilow Cancer Center/Yale school of Medicine, Trumbull, CT, United States |
P312 |
Emicizumab Prophylaxis For The Treatment Of Infants With Severe Haemophilia A Without Factor Viii Inhibitors: Primary Analysis Of The Haven 7 Study 1University of Michigan, Ann Arbor, MI, United States, 2School of Medicine, Cardiff University, Cardiff, United Kingdom, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Sheba Medical Center, Ramat Gan, Israel, 5Tel Aviv University, Tel Aviv, Israel, 6Hospital Universitario La Paz-IdiPaz, Universidad Autónoma, Madrid, Spain, 7Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy, 8Università degli Studi di Milano, Milan, Italy, 9Children’s Hospital Los Angeles, Los Angeles, CA, United States, 10Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany, 11IRCCS Humanitas Research Hospital, Rozzano, Italy, 12Humanitas University, Pieve Emanuele, Milan, Italy, 13Ege University Faculty of Medicine Children's Hospital, Izmir, Turkey, 14Spark Therapeutics, Inc., San Francisco, CA, United States, 15University of Amsterdam, Amsterdam, Netherlands |
P313 |
A Multi-Year Follow-Up Study Of Fidanacogene Elaparvovec Gene Therapy For Hemophilia B 1Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States, 3Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney, Australia, 4Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia, 5Hemophilia Treatment Center, University of California Davis, Sacramento, CA, United States, 6St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, 7Weill Cornell Medicine, New York, NY, United States, 8Mississippi Center for Advanced Medicine, Madison, MS, United States, 9Pfizer Inc, Collegeville, PA, United States, 10Pfizer Srl, Rome, Italy, 11Pfizer Inc, New York, NY, United States |
P314 |
Emergency Department Utilization In A Patient Cohort With Hemophilia: A Single Centre Experience 1Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Calgary, AB, Canada, 2Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Calgary, AB, Canada |
P315 |
Dual Direct Oral Anticoagulant Therapy In Challenging Thrombosis: A Case Series 1The University of British Columbia, Department of Medicine, Division of Hematology, Vancouver, BC, Canada, 2The University of British Columbia Centre for Blood Research, Vancouver, BC, Canada |
P316 |
Recurrent Venous Thromboembolism In A Symptomatic Hemophilia A Carrier 1University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, United States, 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, United States, 3Gulf States Hemophilia and Thrombophilia Center , Houston, TX, United States |
P317 |
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Study Of Human Plasma Derived Antithrombin (Atenativ) In Heparin-Resistant Cardiac Surgery Patients 1Octapharma AG, Lachen, Switzerland, 2Duke University School of Medicine, Durham, NC, United States |
P318 |
An Implementation Dilemma: Rejection Of Thromboprophylaxis Recommendations In The Children&Rsquo;S Likelihood Of Thrombosis (Clot) Trial Vanderbilt University Medical Center, Nashville, TN, United States |
P319 |
Overcoming Distance And Travel Barriers For Virginia Bleeding Disorders Treatment Centers: A Comprehensive Needs Assessment Virginia Commonwealth University, Richmond, VA, United States |
P320 |
Doac&Rsquo;S In The Elderly 1Global Thrombosis Forum , Suwanee , GA, United States, 2Loyola University , Chicago , IL, United States |
3:00 - 5:00 PM | On-Demand/Online |
Online Poster Session |
P801 |
The Role Of Fibrinogen In Changing The Hemostasis Of Patients With Neoplasia And Their Influence On The Microcirculatory Bed Of The Lungs And Control By Anticoagulants SI "Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine" Lviv Ukraine, Lviv, Ukrenia |
P802 |
Antithrombotic Stewardship And Health Equity In Peripheral Artery Disease 1Oklahoma State University Center for Health Sciences Center College of Osteopathic Medicine, Tulsa, OK, United States, 2Oklahoma State University Center for Health Sciences Center College of Osteopathic Medicine, Tahlequah, OK, United States |
P803 |
Platelet Immunophenotype Induced By The Spike (S) Protein And The Rbd Domain Of Sars-Cov-2 Virus. Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico |
P804 |
Correlation Between Abo Blood Types And Disease Severity In Sickle Cell Anemia: Implications For Thrombosis And Hemostasis. 1Lagos University Teaching Hospital , Lagos, Nigeria, 2College of Medicine University of Lagos, Lagos, Nigeria |
P805 |
The Prevalence Of Thrombotic Events Reported Following Sars-Cov2 Vaccine Receipt: Data From The Itp Natural History Study Registry 1Platelet Disorder Support Association, Cleveland, OH, United States, 2Tulane University School of Medicine, New Orleans, LA, United States, 3Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Norris Comprehensive Cancer Center, Los Angeles, CA, United States, 4Vincent Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States |
P806 |
Investigating Inter-Assay Variability Between Doac Calibrated Anti-Factor Xa Assays: A Substudy Of The Pause Trial 1Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 3Department of Medicine, University of Toronto, Toronto, ON, Canada, 4Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada, 5Department of Medicine, McMaster University, Hamilton, ON, Canada, 6The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States, 7Institute of Health System Science - The Feinstein Institutes for Medical Research, Manhasset, NY, United States, 8Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY, United States, 9Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada |
P807 |
Chief: A Retrospective Self-Control Study Of Children <12 With Severe Hemophilia A Without Inhibitors Comparing Emicizumab To Fviii 1Children’s Hospital Los Angeles , Los Angeles, CA, United States, 2WesternU College of Osteopathic Medicine of the Pacific, Pomona, CA, United States, 3Keck School of Medicine, University of Southern California, Los Angeles, CA, United States |
P808 |
The Evaluation Of Mrx Pt Doac Assay For Detection Of Clinically Relevant Factor Xa Inhibitor Drug Levels 1Department of Medicine, McMaster University, Hamilton, ON, Canada, 2Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada, 3Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada, 4Nordic Biomarker, Umeå, Sweden |
P809 |
A Retrospective Study Of Acquired Von Willebrand Syndrome In Myeloproliferative Neoplasms 1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada, 2 Department of Pathology and Laboratory Medicine, King Abdullah Bin Abdulaziz University Hospital, Princess Nourah University, Riyadh, Saudi Arabia, 3 Department of Medicine, McMaster University, Hamilton, ON, Canada, 4 Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada, 5 Hematology/Oncology, Juravinski Cancer Center, Hamilton, ON, Canada |
P810 |
Development Of A Patient Reported Outcome Measure To Study Quality Of Life In Bleeding Disorder Of Unknown Cause 1Division of Hematology and Blood Research Center, University of North Carolina, Chapel Hill, NC, United States, 2Department of Maternal, Child, and Family Health, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, United States, 3Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, United States |
P811 |
Using A Thrombodynamics Test For Diagnostics Of Hypercoagulation In Cancer Patients And Prediction Of Thromboembolic Complications: Preliminary Research Results. 1State Budgetary Healthcare Institution Moscow City Oncology Hospital No. 62 of the Moscow City Health Department, Russian Federation, Moscow, 143515, Moskovskaya area, Krasnogorsk urban district, Istra village, building 27, Moscow, Russia, 2Federal State Budgetary Institution Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation, Russian Federation, Moscow, 117198, Samory Machel street, building 1, Moscow, Russia, 3Federal State Budgetary Institution of Science Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, Russian Federation, Moscow, 109029, Srednyaya Kalitnikovskaya street, building 30, Moscow, Russia |
P812 |
Comparative Analysis Of Bleeding And Thrombotic Risks Among Immune Checkpoint Inhibitors: Insights From The Fda Adverse Event Reporting System 1Oregon Health & Science University, Department of Medicine, Portland, OR, United States, 2Oregon Health & Science University, Department of Medicine, Division of Hematology & Medical Oncology, Portland, OR, United States |
P813 |
Acquired Hemophilia Secondary To The Transplantation Of Hematopoietic Progenitors. A Systematic Review 1Instituto de Investigaciones en Ciencias Biomédicas (INICIB). Universidad Ricardo Palma, Lima, Peru, 2Unidad de Trasplante de Médula Ósea. Hospital Nacional Edgardo Rebagliati-Essalud, Lima, Peru, 3Instituto de Previsión Social, Asuncion, Paraguay |
P814 |
Effect Of Acute Deep Vein Thrombosis In Patients With Lung Cancer In Acute Deep Vein Thrombosis (Dvt): A Study Of The Nation Inpatient Sample John H. Stroger, Jr. Hospital of Cook County, Chicago , IL, United States |
P815 |
Gathering And Disseminating Standardized Gene Therapy Data &Ndash; The World Federation Of Hemophilia Gene Therapy Registry 1University of Washington, Seattle, WA, United States, 2Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, 3World Federation of Hemophilia, Montreal, QC, Canada, 4University Hospital Frankfurt, Frankfurt, Germany, 5Irish Haemophilia Society, Dublin, Ireland, 6University of Michigan, Ann Arbor, MI, United States, 7Institute for Policy Advancement Ltd, Washington, DC, United States |
P816 |
Predicting Pulmonary Embolism In Patients With Deep Venous Thrombosis In The Emergency Department: A Quantitative D-Dimer Diagnostic Approach From A Hospital In Mexico City 1Hospital Español , Mexico City , Mexico, 2Tecnologico de Monterrey , Monterrey , Mexico |
3:45 - 5:15 PM | Sheraton Ballroom I-II |
Health Care Inequitity in the Treatment of VTE |
Chair(s): Anne Rose |
3:45 |
Disparities In Anticoagulation Care Across The Spectrum |
4:15 |
Treatment Of Vte In Rural America |
4:45 |
Maternal Mortality And Pulmonary Embolism In Minority Populations |
3:45 - 5:15 PM | Sheraton Ballroom IV-V |
Take a hike Mickey- novel T&H insights from non-murine animals |
Chair(s): Bobby Lee |
3:45 |
Multispecies Analysis Of The Erad Pathway In Platelet Function |
4:15 |
Deciphering Platelet Cold Storage Lesion In Hibernating Rodents |
4:45 |
Discovering Novel Pro-Coagulant Agents From Snake Venom |
3:45 - 5:15 PM | Chicago Ballroom VII |
Lab support of clinical decision-making in the critically ill bleeding patient |
Chair(s): Marian Rollins-Raval |
3:45 |
How The Lab Can Support Clinical Decision-Making In Acute Critical Bleeding |
4:15 |
Review Of The Use Of Concentrated Clotting Factors Versus Blood Products |
4:45 |
Coagulation Biomarkers And Laboratory Support Of Critically Ill Patients |
5:30 - 6:30 PM | Chicago Ballroom VI |
Clinical & Patient Perspective: A Treatment for Adults with Acute Hepatic Porphyria, including Acute Intermittent Porphyria (Sponsored by: Alnylam Pharmaceuticals) |
Acute hepatic porphyria (AHP) is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. Led by Dr. Angelika Erwin, a consultant of Alnylam Pharmaceuticals, this presentation will provide a disease overview and review the clinical profile of a treatment for adults with AHP, featuring Phase 3 Study results and open-label extension data.
Attendees will also hear from an AHP patient who will share their experience with the disease and treatment. Please join Alnylam Pharmaceuticals and Dr. Erwin to learn more about this treatment for adults with AHP. Dinner will be provided for attendees. |
5:30 - 6:30 PM | Chicago Ballroom IX-X |
Gene Therapy for Hemophilia B: Sharing Experiences in Real-World Settings (Sponsored By: CSL Behring) |
Despite meaningful improvements in treatment for hemophilia B, there remains a need for new therapeutic options that will reduce bleeds, reduce or eliminate the need for routine factor IX prophylaxis, and provide long-term benefits of sustained factor IX activity levels. The first ever FDA-approved gene therapy for hemophilia B is designed to reduce the burden of disease on patients� lives by addressing these unmet needs.
Join our educational product theater session as a team of hemophilia B experts discuss the clinical data and the patient and HCP journey towards treatment as well as share their clinical experiences with gene therapy for hemophilia B. Continuing education credits will not be offered for this program. |
7:00 - 8:00 PM | On-Demand/Online |
Unlocking The Next Step In Gene Therapy For Hemophilia: The End Of The Beginning? (Sponsored by CSL Behring) |
Friday, April 5, 2024 |
6:30 - 8:00 PM | Chicago Promenade |
Registration |
7:00 - 8:00 AM | Chicago Ballroom VI |
Advances in iTTP management - Contemporary Clinical Approaches (Sponsored by Sanofi) |
Please join our Sanofi Medical Affairs Rare Blood Disorders team for our medical symposium to gain expert insights on prioritizing clinical management of aTTP/iTTP, focusing on early treatment, and achieving durable responses from therapies, ultimately resulting in improved clinical outcomes. The symposium will be presented in two parts and will illustratively describe the iTTP pathophysiology, epidemiology/diagnostic considerations, before discussing the ISTH guidelines on diagnosis and treatment of iTTP and important implications on clinical management of iTTP. |
7:00 - 8:00 AM | Chicago Ballroom IX-X |
Hemostasis 2.0: Rethinking Hemophilia Management and Monitoring with Anti-TFPIs and FVIII Mimetics (In partnership with CME Outfitters, LLC. Supported by an educational grant from Novo Nordisk, Inc.) |
In this CME Outfitters live activity, experts in hemophilia, including a patient who has lived with the disorder for many years, discuss the role of these newer therapies, how they work, and how to implement them in practice to improve quality of care and outcomes. A focused exercise in shared decision making keeps the conversation grounded in counseling and care and includes both clinician and patient perspectives.
This activity is certified for 1.0 hours of ACCME, ANCC, AAPA, and ABIM MOC II credit. In-person attendee CE Link: https://myportal.cmeoutfitters.com/course/start/3280d955-5a0b-44e5-902d-f07cf8efc4a0 Virtual attendee CE Link: https://myportal.cmeoutfitters.com/course/start/4f71180e-766e-4789-8097-059646d3524c |
8:15 - 9:45 AM | Sheraton Ballroom I-II |
Not your mom's jeans: Updates on Gene therapy for Hemophilia patients |
Chair(s): Allison Wheeler |
8:15 |
Considering Gene Therapy In The Context Of New Options For Management Of Hemophilia |
8:45 |
Liver Disease In The Era Of Gene Therapy |
9:15 |
Managing Medical Challenges Of Gene Therapy |
8:15 - 9:45 AM | Sheraton Ballroom IV-V |
FXI & FXII |
Chair(s): William Dager |
8:15 |
The Role Of Factor Xii In Ecmo-Associated Thromboinflammation |
8:45 |
Role Of Antiplatelet And Anticoagulant Therapy In Veno-Occlusive Crisis (Voc) |
9:15 |
State Of The Art On Fxi And Fxii Inhibitor Data |
8:15 - 9:45 AM | Chicago Ballroom VII |
Evolution of the Clinical Hemostasis/Thrombosis Laboratory |
Chair(s): Karen Moser |
8:15 |
Evolution Of Hemostasis/Thrombosis Laboratory Physician Role--Clinical Consultant |
8:45 |
Evolution Of Hemostasis/Thrombosis Laboratory Professional Role At The Bench |
9:15 |
Evolution Of Hemostasis/Thrombosis Laboratory Methods Including Laboratory Automation (Elisa-->Lia, Manual-->Automated Adamts13, On-Demand Vs. Batch Testing, New Von Willebrand Assays) |
9:45 - 10:30 AM | Riverwalk AB |
Posters/Exhibits/Break |
P401 |
Analysis Of Pharmacist Interventions Within A Direct Oral Anticoagulation Management Protocol 1University of Wisconsin Health , Madison, WI, United States, 2University of Wisconsin School of Pharmacy , Madison, WI, United States |
P402 |
Characterization Of The Endothelial Cell Subpopulations Marked By Tek And Cdh5 Promoter Driven Cre Expression In Different Mouse Strains 1Life Sciences Institute, University of Michigan, Ann Arbor, MI, United States, 2Department of Pediatrics, University of Michigan, Ann Arbor, MI, United States, 3Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation , Oklahoma City, OK, United States, 4Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States, 5Department of Human Genetics, University of Michigan, Ann Arbor, MI, United States |
P403 |
Electronic Medical Record Interventions In Reducing Inappropriate Testing For Heparin Induced Thrombocytopenia: Experience In A Large Teaching Hospital System 1Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, United States, 2Hematology and Oncology Fellowship, Rochester General Hospital, Rochester, NY, United States, 3Internal Medicine Residency Program, Rochester General Hospital, Rochester, NY, United States, 4Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States, 5Mary M. Gooley Hemophilia and Thrombosis Center, Rochester, NY, United States, 6Department of Hematology and Oncology, Rochester General Hospital, Rochester, NY, United States |
P404 |
Artificial Intelligence And Venous Thromboembolism: Talking To The Experts 1Department of Medicine, Beth Israel Deaconess Medical Center, 2Division of Hematology, Department of Medicine, Beth Israel Deaconess Medical Center,, 3Weber State University, 4Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, 5National Blood Clot Alliance, 6Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 7Division of Blood Disorders and Public Health Genomics, Centers for Disease Control and Prevention, 8Department of Pathology, Cancer Research Institute, Beth Israel Deaconess Medical Center, 9Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 10Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 11Division of General Medicine, Beth Israel Deaconess Medical Center, 12Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, 13Division of Clinical Informatics, Beth Israel Deaconess Medical Center |
P405 |
T-Hlper Cytokine Interactions With Baff In The Factor Viii Immune Response 1Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, United States, 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, United States |
P406 |
Surgical And Procedural Outcomes For Patients With Factor Viii Deficiency Taking Emicizumab Prophylactically: A Regional Approach To Data Collection And Analysis 1Virginia Commonwealth University, Richmond, VA, United States, 2Children's Hospital of Philadelphia, Philadelphila, PA, United States, 3University of Virginia, Charlottesville, VA, United States |
P407 |
Trends Of Acute Ischemic Stroke In Hereditary Hemorrhagic Telangiectasia: A Decade Study 1John H. Stroger Jr Hospital , Chicago, IL, United States, 2Mercy Health- St. Elizabeth Hospital , Youngstown, OH, United States, 3Southern Illinois University Edwardsville, Chicago, IL, United States, 4University of Ilorin, Ilorin, Nigeria, 5Ladoke Akintola University of Technology, Ogbomosho, Nigeria |
P408 |
Sustained Efficacy And Safety 3 Years Following Infusion With Etranacogene Dezaparvovec In Adults With Severe Or Moderately Severe Hemophilia B In The Phase 3 Hope-B Clinical Trial 1Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, United States, 2Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands, 3Center for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium, 4Rigshospitalet, Copenhagen, Denmark, 5Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands, 6Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 7University of North Carolina, Chapel Hill, NC, United States, 8University of South Florida, Tampa, FL, United States, 9University of Southern California Keck School of Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, United States, 10University of Utah, Salt Lake City, UT, United States, 11Vivantes Klinikum im Friedrichshain, Berlin, Germany, 12National Coagulation Centre, St. James’s Hospital, Dublin, Ireland, 13CSL Behring, King of Prussia, PA, United States, 14Division of Haematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium |
P409 |
Long-Term Safety And Efficacy Of Fitusiran Prophylaxis In A Phase 1/2 Open-Label Extension Study In People With Moderate Or Severe Hemophilia A Or B 1University of Michigan, Ann Arbor, MI, United States, 2Clinic Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria, 3Haemophilia, Haemostasis and Thrombosis Centre, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom, 4University Multiprofile Hospital for Active Treatment , Plovdiv, Bulgaria, 5Sanofi, Shanghai, China, 6Sanofi, Cambridge, MA, United States, 7Sanofi, Paris, France, 8University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, United States |
P410 |
Thromboelastometry (Teg): Utility In Diagnosing Of Infection In Neurosurgery Intensive Care Unit (Icu) As Compared To Established Biomarkers AIIMS, New Delhi, India |
P411 |
Fourth Interim Analysis Of The Hem-Powr Study: Evaluating Real-World Effectiveness And Safety Of Damoctocog Alfa Pegol In Previously Treated Patients With Hemophilia A In The United States 1University of Minnesota Medical Center, Minneapolis, MN, United States, 2East Carolina University, Greenville, NC, United States, 3Center for Inherited Blood Disorders, Orange, CA, United States, 4Tulane School of Medicine, New Orleans, LA, United States |
P412 |
Emicizumab Prophylaxis In People With Hemophilia A: Summary Of 10 Years Of Safety Data On Thromboembolic Events And Thrombotic Microangiopathy 1Genentech, Inc., South San Francisco, CA, United States, 2Parexel International, Milan, Italy, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland |
P413 |
Acquired Von Willebrand Syndrome In Monoclonal Gammopathy Of Undetermined Significance: A Focus On Response To Treatment With Ivig 1Division of Internal Medicine, Mayo Clinic, Rochester, MN, United States, 2Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, United States |
P414 |
Title: Recombinant Adamts13 Replacement Therapy In A Pediatric Patient With Congenital Thrombotic Thrombocytopenic Purpura. 1Hemophilia and Thrombosis Center UCSF Benioff Children's Hospitals, Oakland -San Francisco, CA, United States, 2Hemostasis and Thrombosis Center, Children's National Medical Center, Washington , DC, United States |
P415 |
Time To Stable Therapeutic Anticoagulation Using Weight-Based Iv Heparin Dosing Clinical Decisions Support Program University of Illinois Chicago College of Pharmacy, Chicago, IL, United States |
P416 |
Monitoring Bivalirudin Anticoagulant Effect By The Addition Of Diluted Thrombin Time Compared To Activated Partial Thromboplastin Time Alone Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States |
P417 |
Comparative Protamine Sulfate And Hepa-Remove Neutralization Studies In Potency Adjusted Porcine And Bovine Heparin Loyola University Medical Center, Maywood, IL, United States |
P418 |
The Risk Of Recurrent Venous Thromboembolsim And Hemorrhage In The Postpartum Patient Requring Anticoagulation 1Mount Sinai Hospital, Toronto, ON, Canada, 2Department of Medicine, University of Toronto, Toronto, ON, Canada, 3Department of Hematology , University of Toronto, Toronto, ON, Canada, 4Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada, 5Department of Anesthesiology, University of Toronto, Toronto, ON, Canada |
P419 |
Novel Thrombophilia- Prothrombin Belgrade Variant In A Mexican Family 1University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, United States, 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, United States, 3Gulf States Hemophilia and Thrombophilia Center , Houston, TX, United States |
P420 |
&Ldquo;There Is So Much Power In Just Believing Someone&Rdquo;: Understanding The Lived Experiences Of Women With Heavy Vaginal Blood Loss 1Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Department of Obstetrics and Gynecology, Toronto, ON, Canada, 3Division of Emergency Medicine, Toronto, ON, Canada, 44Department of Laboratory Medicine and Pathobiology, St. Michael’s Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada |
10:30 - 11:30 AM | Sheraton Ballroom I-II |
Short Talks - Bleeding Back to the Basics |
Chair(s): Bobby Lee |
10:30 |
Germinal Center And Non-Germinal Center B Cell Response To Factor Viii In Hemophilia A Patients 1Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta/Emory University School of Medicine, Atlanta, GA, United States, 2Stanford University, Palo Alto, CA, United States, 3Department of Pediatrics, Division of Hematology, Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA, United States |
10:45 |
Enhanced Activation Of Fviii Positively Impacts Clot Formation In Vivo Using Hemophilia A Mice 1The Children's Hospital of Philadelphia, Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, United States, 2University of Pennsylvania, Department of Pediatrics, Philadelphia, PA, United States |
11:00 |
Intrinsic Xase Ligand Interactions Impact Fviiia Regulation 1Children's Hospital of Philadelphia, Philadelphia, PA, United States, 2University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States |
11:15 |
Procoagulant Rescue Of Hemophilia B Causing Factor Ix Variants By Factor Fviii Mimetics 1The Children’s Hospital of Philadelphia, Division of Hematology, Philadelphia, PA, United States, 2University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States |
10:30 - 11:30 AM | Sheraton Ballroom IV-V |
Short Talks - Taking Lab Monitoring to the Next Level |
Chair(s): Kristi Smock |
10:30 |
Factor Ii And X (Fiix) Monitored Warfarin Is More Effective Than Pt-Inr Monitored Warfarin And Direct Oral Anticoagulants In Patients Anticoagulated Long-Term For Non-Valvular Atrial Fibrillation. The Greater Reykjavik Oral Anticoagulation (Groac) Study. 1Landspitali National University Hospital, Reykjavik, Iceland, 2University of Vermont, Burlington, VT, United States, 3Massachusetts General Hospital, Boston, MA, United States, 4Harvard University, Boston, MA, United States, 5University of Iceland, Reykjavik, Iceland, 6Sahlgrenska University, Gothenburg, Sweden |
10:45 |
Drop-Of-Blood Coagulation Analysis By I-QattTm 1Department of Biomedical Engineering, Tulane University, New Orleans, LA, United States, 2The University of Texas Medical Branch, Galveston, TX, United States, 3Department of Anesthesiology and Perioperative Medicine, Ochsner Medical Center, New Orleans, LA, United States |
11:00 |
Real-World Use And Correlation Between Platelet-Dependant Activity Assays Of Von Willebrand Factor (Vwf):Ab And Vwf:Gp1Bm In Patients With Von Willebrand Disease In The Age Of The New Guidelines: A Single-Center Study Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN, United States |
11:15 |
Icoaglab Permits Comprehensive Coagulation Profiling In Patients On Percutaneous Cardiac Pump Support Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States |
10:30 - 11:30 AM | Chicago Ballroom VII |
Short Talks - Industry Thrombosis - No CME |
Chair(s): Vinai Bhagirath |
10:30 |
Safety And Efficacy Of Long-Term Treatment Of Type 1 Plasminogen Deficiency Patients With Intravenous Plasminogen Replacement Therapy 1Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, United States, 2Vanderbilt University, Nashville, TN, United States, 3Cedars Sinai Medical Center, Los Angeles, CA, United States, 4Kedrion, Laval, Canada, 5Kedrion, Fort Lee, NJ, United States |
10:45 |
Efficacy And Safety Is Maintained In Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan For Up To 3 Years 1Duke University, Durham, NC, United States, 2Hematology Oncology of Indiana, Indianapolis, IN, United States, 3Ascension St. Vincent Carmel, Carmel, IN, United States, 4University Health Network, Toronto, ON, Canada, 5Ampang Hospital, Ampang, Malaysia, 6The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong, 7Department of Haematology, St. James’s University Hospital, Leeds, United Kingdom, 8Swedish Orphan Biovitrum AB, Stockholm, Sweden, 9Lisa Tan Pharma Consulting Ltd., Cambridge, United Kingdom, 10Apellis Pharmaceuticals, Inc., Waltham, MA, United States, 11French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France, 12Université Paris Cité, Paris, France |
11:00 |
Tolerability And Pharmacodynamic Effect Of Regn9933, A Monoclonal Antibody Directed Against The Factor Xi Apple 2 Domain: Results From A First-In-Human Study 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States, 2Regeneron Pharmaceuticals, Inc. (at time of study), Tarrytown, NY, United States, 3SGS (at time of study), Antwerp, Belgium |
11:15 |
Safety And Efficacy Of Valoctocogene Roxaparvovec Gene Transfer For Severe Hemophilia A: An Update From 4 Years After Treatment 1Adult Hemophilia Treatment Center, University of California San Francisco, San Francisco, CA, United States, 2Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and NHLS, Johannesburg, South Africa, 3Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, 4Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, United States, 5Hemophilia Treatment Center, University of California Davis, Sacramento, CA, United States, 6UNC Blood Research Center, University of North Carolina, Chapel Hill, NC, United States, 7Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, United States, 8Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 9Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 10Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Berlin, Germany, 11Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany, 12Queensland Haemophilia Centre, Cancer Care Services, Royal Brisbane and Women’s Hospital, Brisbane and University of Queensland, Brisbane, Australia, 13Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy, 14Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy, 15BioMarin Pharmaceutical Inc., Novato, CA, United States, 16Hemocentro UNICAMP, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil |
11:45 - 12:45 PM | Chicago Ballroom VI |
The Role of the Liver in Hemophilia Gene Therapy & Clinical Implications (Sponsored by Pfizer) |
The advent of liver directed-gene therapies in hemophilia has placed increasing interest on liver health in the pre and post infusion settings. This session will explore the role of the liver in hemophilia gene therapy including evaluation of liver heath and key considerations for clinical management from a hepatologist�s perspective. |
11:45 - 12:45 PM | Chicago Ballroom IX-X |
VONVENDI Prophylaxis for Severe Type 3 von Willebrand Disease - Patient Case Discussion (Sponsored by Takeda Pharmaceuticals) |
Join our expert HCP and a patient living with von Willebrand Disease (VWD) for an interactive journey. Our panel will guide you through the patient�s experience with VWD, review their treatment history, and discuss how VONVENDI may be added to the treatment plan for prophylaxis. |
12:45 - 1:30 PM | Riverwalk AB |
Posters/Exhibits/Break |
P502 |
Evaluation Of Anticoagulation Management In Patients With Suspected Heparin-Induced Thrombocytopenia Awaiting Diagnosis Confirmation Brigham and Women's Hospital, Boston, MA, United States |
P503 |
Natural History Of Bleeding, Transfusion, And Antibody Prevalence In A Subset Of Hermansky-Pudlak Syndrome Patients: Effects Of Freeze-Dried Lyophilized Platelet Derived Hemostat Ex Vivo Cellphire Therapeutics, Inc., Rockville, MD, United States |
P504 |
Chimeric Antigen Receptor (Car) T Cell Treatment In Very High Titer Inhibitor Murine Model Requires Cd19 And Bcma Targeting 1Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, 2The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, United States, 3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States |
P505 |
Normalization Of Thrombin Generation Results Using Within-Run Plasma Normalizator Simultaneously. 1Landspitali - The National University Hospital, Reykjavik, Iceland, 2The University of Iceland, Reykjavik, Iceland |
P506 |
Two-Center External Validation Of A Machine Learning Natural Language Processing (Nlp) Algorithm For Venous Thromboembolism (Vte) Ascertainment 1Baylor College of Medicine, Houston, TX, United States, 2VA Boston Healthcare System, Boston, MA, United States, 3Harvard Medical School, Boston, MA, United States, 4University of Texas Health Science Center at Houston, Houston, TX, United States, 5UPMC Harrisburg, Harrisburg, PA, United States, 6Beth Israel Deaconess Medical Center, Boston, MA, United States |
P507 |
Child Hemo-Tem Observer-Reported Outcome Measure: Understanding And Assessing Treatment Burden In Children With Hemophilia 1The Brod Group, Mill Valley, CA, United States, 2Evidera|PPD, Bethesda, MD, United States, 3Novo Nordisk A/S, Søborg, Denmark, 4Novo Nordisk Inc., Plainsboro, NJ, United States |
P508 |
Long-Term Evaluation Of Liver Health In Participants Who Received Fidanacogene Elaparvovec: Data From A Phase 1/2A Study With Up To 6 Years Of Follow Up 1UC David Comprehensive Cancer Center, Sacramento, CA, United States, 2Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 3Centenary Institute, Sydney, Australia, 4Weill Cornell Medical Center, New York, NY, United States, 5University of Toronto, Toronto, ON, Canada, 6University of Pennsylvania, Philadelphia, PA, United States, 7Pfizer Inc, New York, NY, United States |
P509 |
Emicizumab For Severe Von Willebrand Disease (Vwd) And Vwd/Hemophilia A: The Emivwd Study 1Bleeding & Clotting Disorders Institute, Peoria, IL, United States, 2Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, United States |
P510 |
Design Of A Prospective, Observational, Multicenter Study Of The Effectiveness Of Efanesoctocog Alfa On Long-Term Joint Health In Patients With Hemophilia A In The United States And Japan 1Bleeding & Clotting Disorders Institute, Peoria, IL, United States, 2Mississippi Center for Advanced Medicine, Madison, MS, United States, 3Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States, 4Orthopedic Hemophilia Treatment Center, Los Angeles, CA, United States, 5Sanofi, Cambridge, MA, United States, 6Sanofi, Amsterdam, Netherlands |
P511 |
Seroprevalence And Seroconversion Among People With Hemophilia A In The United States: Observations From The Saavy (Seroprevalence Of Aav Antibody) Study 1Indiana Hemophilia Thrombosis Center, Indianapolis, IN, United States, 2National Bleeding Disorders Foundation, New York, NY, United States, 3Rush University, Chicago, IL, United States, 4BioMarin Pharmaceutical, Novato, CA, United States, 5BioMarin Pharmaceutical, London, United Kingdom, 6Hemostasis and Thrombosis Center, UC Davis Health, Sacramento, CA, United States, 7Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, United States |
P512 |
Real-World Data On Emicizumab Prophylaxis In Older Persons With Hemophilia A: A Retrospective Single Center Cohort Study 1Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, United States, 2Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States, 3Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, United States |
P513 |
Clinical Utility And Performance Of Von Willebrand Factor Activity Assays In A National Reference Laboratory: The Vitalant Coagulation Laboratory&Rsquo;S Experience With The Ristocetin Cofactor And Vwf:Gp1Bm Assays 1Vitalant Coagulation Laboratory, Pittsburgh, PA, United States, 2Department of Pathology, University of Pittsburgh, Pittsburgh, PA, United States |
P514 |
Brain Volumes And Neurocognitive Outcomes In Children With Hemophilia A 1Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, United States, 2*Current Location - Mayo Clinic , Rochester, MN, United States, 3Department of Psychiatry, University of Iowa, Iowa City, IA, United States, 4*Current Location -University of Arkansas for Medical Sciences, Pediatrics Arkansas Children's Hospital, Hematology/Oncology, Little Rock, AR, United States, 5The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, IA, United States, 6Iowa Neuroscience Institute, Iowa City, IA, United States |
P515 |
Single Center Retrospective Comparison Of Bivalirudin And Heparin For Therapeutic Anticoagulation In Pediatric Patients Children's Mercy Hospital, Kansas City, MO, United States |
P516 |
Transitioning From Oral Factor Xa Inhibitor To Unfractionated Heparin Using Heparin-Calibrated Anti-Xa Levels 1UW Health - Madison, Madison, WI, United States, 2University of Wisconsin School of Pharmacy , Madison, WI, United States, 3UW Health - Northern Illinois , Rockford, IL, United States |
P517 |
Covid-19 Venous Thromboembolism Prophylaxis Guidelines 1Children's Mercy Kansas City, Kansas City, MO, United States, 2University of Missouri-Kansas City, Kansas City, MO, United States |
P518 |
Benefit Of Albumin Infusion In An Elderly Cirrhotic Patient On Doac: About A Case . 1APHP René Muret , Sevran, France, 2APHP Jean Verdier , Bondy, France, 3APHP Avicenne, Bobigny, France |
P519 |
The Severe Von Willebrand Disease Patient Registry: A Longitudinal Natural History And Patient Outcomes Study 1VWD Connect Foundation , Wellington , FL, United States, 2Icahn School of Medicine Mount Sinai Hospital, New York , NY, United States |
P520 |
Effect Of Doac Stop On Coagulation Factor Activity Levels 1ARUP Laboratories Institute for Clinical and Experimental Pathology, Salt Lake City, UT, United States, 2University of Utah Department of Pathology |
1:30 - 2:45 PM | Sheraton Ballroom IV-V |
Abortion/Reproductive Health - When the law and healthcare collide - How laws that restrict access to reproductive care are affecting hemostasis and thrombosis patients |
Chair(s): Julie Jaffray |
1:30 |
Effect On Stem Cell Research |
1:55 |
Post-Roe&Rsquo;S Downstream Effects - Impacting Patients, Personnel & Trainees |
2:20 |
Impact On Clinical Care Thrombosis And Hemostasis |
3:00 - 4:30 PM | Sheraton Ballroom I-II |
Ouch! Pain and Bleeding Disorders |
Chair(s): Bethany Samuelson Bannow |
3:00 |
Biopsychosocial Pain Mechanisms |
3:30 |
Interdisciplinary Pain Assessment |
4:00 |
Barriers And Successes To Implementing Interdisciplinary Multimodal Pain Management |
3:00 - 4:30 PM | Sheraton Ballroom IV-V |
Clinical Challenges for Antithrombotic Management in the Ambulatory Care setting |
Chair(s): Anne Rose |
3:00 |
De-Escalating Antithrombotic Therapy: How Do We Ensure Appropriate Use |
3:30 |
Perioperative Considerations For Anticoagulation With Mechanical Devices And Heart Valves |
4:00 |
Keeping Anticoagulation Clinics Relevant In The Next Decade |
3:00 - 4:30 PM | Chicago Ballroom VII |
Immunothrombotic Syndromes |
Chair(s): Cathy Hayward |
3:00 |
Machine Learning For Hit |
3:30 |
Immunothrombosis And Septicemia |
4:00 |
Complement Activation By Hit Immune Complexes |
4:30 - 5:15 PM | Riverwalk AB |
Posters/Exhibits/Break |
P601 |
Il-6-Induced Potentiation Of Platelet Activity And Glycosylation In Venous Thromboembolism 1Pediatric Hematology/Oncology/Bone Marrow Transplant, Children’s Wisconsin and Medical College of Wisconsin, Milwaukee, WI, United States, 2Translational Glycomics Center, Versiti Blood Research Institute, Milwaukee, WI, United States |
P602 |
Platelet-Nucleic Acid Receptor Promotes Pulmonary Thrombo-Inflammation In Sickle Cell Disease 1Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI, United States, 2Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States |
P603 |
Athn Transcends: Natural History Cohort Study Of Bleeding Symptoms And Treatment Outcomes In Patients With Glanzmann Thrombasthenia 1Arkansas Children’s Hospital, University of Arkansas for Medical Sciences, Little Rock, AR, United States, 2Rainbow Babies & Children’s Hospital, Case Western Reserve University, Cleveland , OH, United States, 3American Thrombosis and Hemostasis Network, Rochester, NY, United States, 4Hemab Therapeutics, Cambridge, MA, United States, 5National Bleeding Disorders Foundation, New York, NY, United States, 6Yale University School of Medicine, New Haven, CT, United States, 7Central Michigan University/Children’s Hospital of Michigan, Detroit, MI, United States |
P604 |
Anti-GpibΑ Antibodies In Fnait Are Associated With Recurrent Miscarriages 1Department of Laboratory Medicine and Pathobiology, University of Toronto., Toronto, ON, Canada, 2Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, Toronto, ON, Canada, 3Toronto Platelet Immunology Group, Toronto, ON, Canada, 4Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, 5Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto., Toronto, ON, Canada, 6The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 7Department of Physiology, University of Toronto, Toronto, ON, Canada, 8Department of Medicine, University of Toronto, Toronto, ON, Canada |
P605 |
Utility Of Thromboelastography With Platelet Mapping (Teg-Pm) For Monitoring Platelet Transfusion In Qualitative Platelet Disorders 1Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States |
P606 |
Title: Real-World Efficacy Data On Adolescent Hemophilia A Patients Transitioning To Bay 81-8973 Or Bay 94-9027 In The Athndataset 1American Thrombosis & Hemostasis, Rochester, NY, United States, 2Bayer Pharmaceuticals, USA, Whippany, NJ, United States, 3National Bleeding Disorders Foundation, New York City, NY, United States, 4Yale University School of Medicine, New Haven, CT, United States |
P607 |
Burden Of Disease And Impact On Quality Of Life In Hereditary Factor X Deficiency Patients Who Were Diagnosed At Birth: Findings From The Hereditary Factor X Deficiency In America Survey 1Kedrion Biopharma, INC., Fort Lee, NJ, United States, 2AESARA, INC., Chapel Hill, NC, United States, 3Versiti Blood Research Institute, Medical College of Wisconsin, and Children's Wisconsin, Milwaukee, WI, United States |
P608 |
Rebleed Incidence With Eptacog Beta Treatment Through 24 And 48 Hours In Children (Under 12 Years) With Hemophilia A Or B With Inhibitors 1Nationwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, OH, United States, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Central Michigan University College of Medicine/Children’s Hospital of Michigan, Carmen and Ann Adams Department of Pediatrics, Division of Hematology/Oncology, Detroit, MI, United States, 4Pediatric Hemophilia Treatment Center, University of Miami, Miami, FL, United States, 5Center for Inherited Blood Disorders, Orange, CA, United States, 6Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States, 7Department of Pediatrics, Division of Pediatric Hematology/Oncology, Weill Cornell Medicine, New York, NY, United States, 8Banner MD Anderson Cancer Center, Gilbert, AZ, United States, 9Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, United States, 10American Thrombosis and Hemostasis Network, Rochester, NY, United States, 11Hemophilia and Thrombosis Treatment Center, Rady Children's Hospital-San Diego, San Diego, CA, United States, 12Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, United States, 13Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO, United States, 14University of Michigan, Ann Arbor, MI, United States |
P609 |
Recurrent Pregnancy Loss In Type 3 Von Willebrand Disease With A Unique Mutation Profile Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, United States |
P610 |
Value Of Functional Protein S Activity Assays For Detection Of Type Ii Protein S Deficiency Cleveland Clinic Foundation, Cleveland, OH, United States |
P611 |
Validating The Jakpot Prediction Rule For Identifying Which Patients With Erythrocytosis Are Unlikely To Have A Jak2 Mutation 1Beth Israel Deaconess Medical Center, Boston, MA, United States, 2Yale Medical Center, New Haven, CT, United States |
P612 |
Clinical Outcomes In Mild-Moderate And Severe Patients With Hemophilia B: Results From A Real-World, Multi-National Survey 1Pfizer Inc, New York, NY, United States, 2Adelphi Real World, Bollington, United Kingdom |
P613 |
Outcomes In North American Participants Who Received Efanesoctocog Alfa Prophylaxis In The Xtend-1 Study 1Division of Hematology/Oncology, Department of Medicine, University of California San Diego, San Diego, CA, United States, 2Department of Pediatrics, University of Florida, Gainesville, FL, United States, 3Luskin Orthopaedic Institute for Children, Los Angeles, CA, United States, 4Department of Pediatrics, McMaster Children’s Hospital, McMaster University, Hamilton, ON, Canada, 5Division of Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, United States, 6Division of Hematology & Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada, 7Sanofi, Cambridge, MA, United States, 8Sanofi, San Diego, CA, United States, 9Sanofi, Bridgewater, NJ, United States |
P614 |
Health-Related Quality Of Life And Treatment Burden In Patients With Hemophilia A/B Without Inhibitors On Concizumab Prophylaxis: Results From The Phase 3 Explorer8 Study 1Hemostasis and Thrombosis Center, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States, 2Department of Hematology, Belfast Health and Social Care Trust, Belfast, Ireland, 3Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, Saar, Germany, 4Department of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa, 5Novo Nordisk A/S, Søborg, Denmark, 6Department of Haematology, Ampang Hospital, Selangor, Malaysia, 7Ronald Sawers Haemophilia Treatment Centre, Monash University, Melbourne, Australia, 8Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan, 9Novo Nordisk Inc., Plainsboro, NJ, United States |
P615 |
Anticoagulant Management Of Cancer-Associated Thrombosis And Thrombocytopenia: A Retrospective Chart Review 1Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, 2Department of Translational Health Science, University of Windsor, Windsor, ON, Canada, 3Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada, 4Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada, 5Windsor Regional Hospital, Windsor, ON, Canada |
P616 |
A Survey Of Clinician Practice Patterns On The Use Of Inferior Vena Cava Filters For Venous Thromboembolism 1WE-SPARK Health Institute, Windsor, ON, Canada, 2Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, 3Department of Biomedical Sciences, University of Windsor, Windsor, ON, Canada, 4Lawson Health Research Institute, London, ON, Canada, 5Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada, 6Ottawa Hospital Research Institute, Ottawa, ON, Canada, 7Windsor Regional Hospital, Windsor, ON, Canada |
P617 |
Inr Above Five Warfarin Events Inpatient Require Focus On Preventable Cases To Lower Incidence 1Froedtert and Medical College of Wisconsin, MIlwaukee, WI, United States, 2Versiti Blood Center of Wisconsin, Milwaukee, WI, United States |
P618 |
Evaluation Of Nurse-Managed Heparin Nomogram Adherence After Implementation Of An Electronic Medical Record-Embedded Heparin Calculator 1Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, United States, 2Department of Nursing, The Johns Hopkins Hospital, Baltimore, MD, United States, 3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States |
P619 |
A Comparison Of Targeted High-Range Versus Low-Range Anti-Xa Goal For Intravenous Unfractionated Heparin In Patients With Mechanical Circulatory Support Devices Henry Ford Hospital, Detroit, MI, United States |
5:15 - 6:45 PM | Sheraton Ballroom I-II |
Anticoagulation for patients with bleeding related conditions |
Chair(s): Vinai Bhagirath |
5:15 |
Anticoagulants In Patients With Bleeding Disorders |
5:45 |
Describing The Risks For Bleeding And Thrombosis Unique To Patients With Renal Impairment |
6:15 |
Resumption Of Anticoagulation Post Bleeding Event |
5:15 - 6:45 PM | Sheraton Ballroom IV-V |
Cutting to the chase- Fibrinolysis |
Chair(s): Jordan Shavit |
5:15 |
Engineering Devices To Measure And/Or Enhance Fibrinolysis |
5:45 |
Tfpi As A Modifier Of Fibrinolysis And Bleeding In Fxi Deficiency |
6:15 |
Intersection Of Fibrin(Olysis) And Inflammation At The Oral Mucosa Barrier |
5:15 - 6:45 PM | Chicago Ballroom VII |
Dissolving the Clot of Thrombilia Testing: Current Diagnostic Updates and Challenges |
Chair(s): Karen Moser |
5:15 |
Updates On Protein C And Protein S Deficiency Testing (Highlights And Critiques Of Recent Isth Documents) |
5:45 |
Challenges In Practical Application Of La Testing Guidelines In North America: Mixing Studies And Beyond! |
6:15 |
Pitfalls And Considerations For Thrombophilia Testing--How Can Laboratories Support Patients? (Purpura Fulminans, Acute Dic, Apas, Interferences Etc.) |
7:00 - 8:00 PM | Chicago Ballroom VI |
Elevating Hemophilia Care Beyond Bleed Management: A Multidisciplinary Panel Dialogue to Bridge Gaps in Patient Care (Sponsored by Sanofi) |
Please join us for our panel of healthcare providers and patients/caregivers for a discussion on current unmet needs in hemophilia centered around findings from a Hemophilia Life Stages and Changes Global Survey of >2,700 patients, caregivers, and hematologists. As treatment options evolve, so must expectations and goals on management of hemophilia. This symposium will explore how communication gaps between HCPs and patients can improve to achieve positive change and better quality of life. |
7:00 - 8:00 PM | Chicago Ballroom IX-X |
Ask the Experts: Navigating Gene Therapy for Hemophilia - Lived Experience Perspectives from Patients and Providers (Sponsored by BioMarin) |
Join us for dinner and hear from a panel of health care providers with hemophilia gene therapy experience (clinical trial and post-FDA approval), as well as patients with years of post-treatment experience. Panelists will review clinical trial data and discuss patient treatment outcomes and expectations. Have your questions answered by the panel and learn how gene therapy can be implemented in your Hemophilia Treatment Center. |
Saturday, April 6, 2024 |
6:30 - 1:00 PM | Chicago Promenade |
Registration |
7:00 - 8:00 AM | Chicago Ballroom VI |
Finding the Trusted Factor: 10 Years of FIX Experience Across Ages and Settings (Sponsored by Sanofi) |
This presentation highlights a decade of experience (since FDA approval) with a Factor IX therapy, exploring its impact across various age groups and settings. You will hear from clinical experts and a patient as they share insights and experience with an EHL FIX therapy that has been trusted for 10 years. |
7:00 - 8:00 AM | Chicago Ballroom IX-X |
Paradigm Shifts in Hemophilia Prophylaxis: Putting Evidence Into Practice (Sponsored by Clinical Care Options, LLC) |
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Joint Accreditation Statement In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician Continuing Medical Education CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Evaluation: http://www.clinicaloptions.com/HemophiliaChicago2024Eval Slides/Resources: www.clinicaloptions.com/HemophiliaChicago2024Program |
8:15 - 9:45 AM | Sheraton Ballroom I-II |
Bleeding in Hypermobility/Ehlers Danlos |
Chair(s): Bobby Lee |
8:15 |
Assessment And Management Of Bleeding In Pediatric Patients With Hypermobility Syndrome |
8:45 |
Pregnancy Complications And Outcomes In Ehlers Danlos Syndrome |
9:15 |
Contribution Of Platelet Dysfunction To Bleeding In Ehlers Danlos Syndrome |
8:15 - 9:45 AM | Sheraton Ballroom IV-V |
Young, Wild and VTE - Treatment Considerations for Adolescents and Young Adults |
Chair(s): Julie Jaffray |
8:15 |
Pulmonary Embolus In Adolescents: Treatment Challenges And Opportunities |
8:45 |
Continuing "The Pill" Or Not?: Vte Treatment And Exogenous Hormones |
9:15 |
The Changing Landscape Of Anticoagulation Treatment In Children |
8:15 - 9:45 AM | Chicago Ballroom VII |
Quality Improvement Efforts in Laboratory Hemostasis/Thrombosis Testing |
Chair(s): Marian Rollins-Raval |
8:15 |
Preanalytic Variables -- (Updates Including Clsi) |
8:45 |
Factor Xiii Testing- What Is Available? What Are Best Practices For Testing? Effect Of Concentrates On Lab Tests? Antigen Versus Activity Testing? Any Remaining Role For Clot Solubility? |
9:15 |
Platelet Aggregation Testing In Thrombocytopenic Patients |
9:45 - 10:30 AM | Riverwalk AB |
Posters/Exhibits/Break |
P701 |
Necessity Of Anti-Xa Level Monitoring For Prophylactic Enoxaparin In Children And Adolescents: A Single Institution Experience 1Texas Children's Hospital, Houston, TX, United States, 2Baylor College of Medicine, Houston, TX, United States |
P703 |
Insight Into Athn 16: Treatment Of Bleeding Events In Patients With Congenital Hemophilia A Or B With Inhibitors To Evaluate The Safety Of Coagulation Factor Viia (Recombinant)-Jncw 1American Thrombosis and Hemostasis Network, Rochester, NY, United States, 2Northwell Health Hemostasis and Thrombosis Center, New Hyde Park, NY, United States, 3University Hospitals Health System Cleveland, Cleveland, OH, United States, 4Children’s Mercy Kansas City, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States, 5Central Michigan University/Children’s Hospital of Michigan, Detroit, MI, United States, 6University of Texas Health Science Center, Houston, TX, United States, 7Willett Children's Hemophilia Treatment Center at Memorial Health, Savannah, GA, United States, 8Arnold Palmer Hospital for Children, Orlando, FL, United States, 9Henry Ford Health System, Detroit, MI, United States, 10Louisiana Center for Advanced Medicine, Slidell, LA, United States, 11Mayo Clinic, Rochester, MN, United States, 12National Blood Disorders Foundation, New York, NY, United States, 13Mississippi Center for Advanced Medicine, Madison, MS, United States, 14Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, United States, 15Vanderbilt University Medical Center, Nashville, TN, United States, 16University of Minnesota Medical Center, Minneapolis, MN, United States |
P704 |
Impact Of Mrna Covid-19 Vaccination On D-Dimer Levels And Anti-Pf4 Seroconversion In Healthy Adults: A Systematic Review Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, United States |
P705 |
Utility Of Thromboelastography Versus Routine Coagulation Tests: Cardiac Bypass Surgery. Hospital Universitario Virgen del Rocio, SEVILLA, Spain |
P706 |
Clinical Outcomes Of Congenital Thrombotic Thrombocytopenic Purpura With And Without Prophylaxis Therapy: A Multinational Chart Review Study 1APHP.6–Reference Center for Thrombotic Microangiopathies (CNR-MAT), Hôpital St Antoine, Paris, France, 2University College London Hospitals NHS Foundation Trust, London, United Kingdom, 3Department of Hematology and Central Hematology Laboratory, Bern University Hospital, Bern, Switzerland, 4HCD Economics, Knutsford, United Kingdom, 5Takeda Development Center Americas, Inc., Cambridge, MA, United States |
P707 |
The Impact Of Multidisciplinary Perinatal Care For Women With Bleeding Disorders 1Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada, 3Department of Obstetrics and Gynecology, St. Michael’s Hospital, Toronto, ON, Canada, 4Department of Pediatrics, St. Michael’s Hospital, Toronto, ON, Canada, 5Department of Paediatrics, Division of Haematology-Oncology, The Hospital for Sick Children, Toronto, ON, Canada, 6Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 7St. Michael's Hospital, University of Toronto, Toronto, ON, Canada, 8Department Of Anaesthesia, University of Toronto, Toronto, ON, Canada, 9Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 10Li Ka Shing Knowledge Institute, Toronto, ON, Canada |
P708 |
Temporal Trends And Predictors Of Venous Thromboembolism In Hospitalized Chronic Lymphocytic Leukemia Patients 1Lincoln Medical and Mental Health Centre, Bronx, NY, United States, 2Montefiore Medical Centre, Bronx, NY, United States, 3University of Benin Teaching Hospital , Benin, Nigeria |
P709 |
Deep Phenotyping Reveals A High Prevalence Of Distressing Bleeding Symptoms In Patients With Hypermobile Ehlers Danlos Syndrome (Heds) Spectrum Disease . 1St. Jude Children’s Research Hospital, Memphis, TN, United States, 2University of Arizona, Tucson, AZ, United States, 3Carle Illinois College of Medicine, Urbana, IL, United States, 4Carle Foundation Hospital, Urbana, IL, United States |
P710 |
Indirect Comparison Of Prophylaxis Efficacy Between Simoctocog Alfa And Efanesoctocog Alfa In Severe Hemophilia A And Their Cost In The United States 1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, DC, United States, 2University of Miami-Miller School of Medicine, and University of Miami-Hemophilia Treatment Center, Miami, FL, United States |
P711 |
Risk Of Thrombosis In Sglt2 Inhibitor-Associated Erythrocytosis: A Multi-Center Propensity-Matched Analysis 1Division of Hematology and Medical Oncology, Virginia Commonwealth University Health, Richmond, VA, United States, 2Massey Cancer Center, Richmond, VA, United States |
P712 |
Hospitalization Outcomes From Venous Thromboembolism In Cancer Patients: An Analysis Of The National Inpatient Sample Data From 2016 To 2019 John H. Stroger Jr Hospital , Chicago, IL, United States |
P713 |
Accurate Measurement Of Factor Viii Activity And Inhibitors In The Presence Of Mim8 1Labcorp Colorado Coagulation, Englewood, CO, United States, 2Novo Nordisk A/S, Søborg, Denmark, 3Novo Nordisk Inc., Plainsboro, NJ, United States |
P714 |
First Real-World Experience Administering Etranacogene Dezaparvovec Gene Therapy For People With Hemophilia B 1Hemophilia Outreach Center, Green Bay, WI, United States, 2CSL Behring, King of Prussia, PA, United States, 3University of South Florida, Tampa, FL, United States |
P715 |
Thrombosis Rates And Use Of Thromboprophylaxis After Discharge From Gynecologic Cancer-Related Surgery University of Miami, Miami, FL, United States |
P716 |
Incidence Of Gastrointestinal Bleeding In High-Risk Cardiovascular Patients Taking Antithrombotic Medications With Proton Pump Inhibitors 1University of Michigan-Michigan Medicine, Ann Arbor, MI, United States, 2Henry Ford Health- Division of Hospital Medicine, Detroit, MI, United States, 3Trinity Health-Ann Arbor, Ann Arbor, MI, United States, 4Ascension- St. John Hospital, Detroit, MI, United States |
P717 |
Accuracy Of A Warfarin Clinical Dosing Algorithm Enriched With Genetic Information Compared To The Use Of Clinical Algorithm 1Hamad Medical Corporation, Doha, Qatar, 2College of Pharmacy, QU Health, Qatar University, Doha, Qatar |
P718 |
Safety And Cost-Effectiveness Analysis Of Anticoagulation Therapy In Adult Patients Undergoing Extracorporeal Membrane Oxygenation 1Department of Health Economics and Outcomes Research, Grifols SSNA, Research Triangle Park, NC, United States, 2University of North Carolina at Charlotte, College of Health and Human Services, Department of Public Health Sciences , Charlotte, NC, United States |
P719 |
What Is The Role Of Family History In The Management Of Vte? 1Global Thrombosis Forum , Suwanee , GA, United States, 2Loyola University , Chicago, IL, United States, 3Northshore University Health System , Evanston, IL, United States |
10:30 - 11:30 AM | Sheraton Ballroom I-II |
Short Talks - Bleeding: Outcomes and Predictors |
Chair(s): Bethany Samuelson Bannow |
10:30 |
Social Vulnerability And Hemophilia Care And Outcomes 1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States, 2Division of Blood Disorders and Public Health Genomics, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, United States, 3Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, United States |
10:45 |
Heavy Menstrual Bleeding May Be Driven By Localized Endometrial Coagulopathy 1Hemostasis & Thrombosis Center at Oregon Health & Science University, Portland, OR, United States, 2Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, United States |
11:00 |
Agnostic Identification Of Plasma Biomarkers For Postpartum Hemorrhage Risk 1Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States, 2Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, The George Washington University School of Medicine and Health Science, Washington, DC, United States, 3Biochemistry and Molecular Genetics, The University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 4Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, and Department of Medicine under Hematology, Duke University School of Medicine, Durham, NC, United States, 5Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States |
11:15 |
Individual Pharmacokinetic Evaluation Of Fixed-Sequence Single-Dose Octocog Alfa, Rurioctocog Alfa Pegol, And Efanesoctocog Alfa In Adults With Severe Hemophilia A 1Division of Hematology/Oncology, Department of Pediatrics, Carver College of Medicine, University of Iowa Stead Family Children's Hospital, Iowa City, IA, United States, 2Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia, Bulgaria, 3McMaster Children’s Hospital, McMaster University, Hamilton, ON, Canada, 4Sanofi, Cambridge, MA, United States, 5Sanofi, Amsterdam, Netherlands |
10:30 - 11:30 AM | Sheraton Ballroom IV-V |
Short Talks - Thrombosis - Special Populations |
Chair(s): Gabriela Cesarman-Maus |
10:30 |
Reclassification Of Antiphospholipid Antibody Syndrome According To The 2023 Acr/Eular Guidance In A Pharmacist Directed Anticoagulation Clinic 1SUNY Upstate Medical University, Syracuse, NY, United States, 2St. John Fisher University, Wegmans School of Pharmacy, Rochester, NY, United States |
10:45 |
Understanding Primary Antiphospholipid Syndrome: Correlating Antiphospholipid Antibodies Profile And Titers With Thrombotic And Hematological Activity Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City , Mexico |
11:00 |
Nationally Representative Data On Co-Diagnosis, Mortality And Healthcare Burden Of Venous Thromboembolism In Hospitalized Covid-19 Patients: Results From The National Inpatient Sample 1Southern Illinois University School of Medicine, Springfield, IL, United States, 2SIU School of Medicine P4P program, Springfield, IL, United States, 3Vitalant Research Institute, San Francisco, CA, United States, 4University of Texas Southwestern School of Medicine, Dallas, TX, United States, 5Case Western Reserve University School of Medicine, Cleveland, OH, United States, 6Johns Hopkins University School of Medicine, Baltimore, MD, United States, 7Vitalant Corporate Medical Affairs, Scottsdale, AZ, United States |
11:15 |
Health Literacy In Pediatric Thrombosis Patients And Parents/Caregivers The Hospital for Sick Children, Toronto, ON, Canada |
10:30 - 11:30 AM | Chicago Ballroom VII |
Short Talks - Insights on Platelet Biology |
Chair(s): Cathy Hayward |
10:30 |
Evaluating Diagnostic Algorithms For Heparin-Induced Thrombocytopenia Using Two Combined Rapid Automated Assays 11. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada, 2Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 3. Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada, 32. Michael G. DeGroote Centre for Transfusion Research, McMaster University, 4. Department of Statistics and Actuarial Science, University of Waterloo,, Hamilton, ON, Canada, 41. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada, 51. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada |
10:45 |
Dna Damage Repair Inhibition: A Catalyst For Enhanced Megakaryopoiesis And Thrombopoiesis 1Vascular Biology Program, Boston Children's Hospital, Boston, MA, United States, 2Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States |
11:00 |
Novel Mechanism Of Thrombosis And Hemostasis Involving Platelet Alpha-Dystroglycan 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 2Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, ON, Canada, 3Canadian Blood Services Centre for Innovation, Toronto, ON, Canada, 4Department of Medicine, University of Toronto, Toronto, ON, Canada, 5Department of Biochemistry, University of Toronto, Toronto, ON, Canada |
11:15 |
Unc9426, A Selective Tyro3 Inhibitor, Decreases Human Platelet Activation And Increases Survival In A Murine Pulmonary Embolism Model 1Versiti Blood Research Institute, Wauwatosa, WI, United States, 2Aflac Cancer and Blood Disorders Center and Children's Healthcare of Atlanta, Atlanta, GA, United States, 3Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States |
11:45 - 1:00 PM | Sheraton Ballroom IV-V |
Shared decision making between patients and clinicians |
Chair(s): Leslie Lake |
11:45 |
How Can Clinicians Help Patients Make Decisions That Align With Their Values? |
12:10 |
Shared Decision Making When There Are Limited Data - Hemophilia Gene Therapy |
12:35 |
Patient Involvement In Guidelines - The Experience With The Ash Pediatric Vte Guideline |